ABSTRACT - 598270 Disclosed herein is a use of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone-sulfate, androst-5-ene-3?,17?-diol, and 4-androsten-3,17-dione in the manufacture of a medicament for treating and/or reducing the likelihood of acquiring symptoms or diseases due to the menopause, in postmenopausal women, wherein the symptoms or diseases due to the menopause are selected from the group of diseases consisting of Osteoporosis, vaginal atrophy, vulvo-vaginal dryness, hypogonadism, diminished libido, skin atrophy, connective tissue disease, urinary incontinence, breast, endometrial, ovarian and uterine cancers, hot flashes, loss of muscle mass, insulin resistance, fatigue, loss of energy, aging, and physical symptoms and signs of menopause, wherein said medicament is formulated for administration of the sex steroid precursor to a patient in need of said treatment at a therapeutic amount which increases the level of circulating androgen metabolites, namely, androsterone glucuronide (ADT-G), androstane-3(,17(-diol-3-glucuronide (3(-diol-3G), and androstane-3(,17(-diol-17-glucuronide (3(-diol-17G), as part of a combination therapy with a therapeutically effective amount of a Selective Estrogen Receptor Modulator (particularly acolbifene) in order to decrease the risk of breast and uterine cancer normally present in postmenopausal women and to prevent bone loss, fat accumulation and diabetes type 2. Said medicament is also suitable for treating and/or reducing the likelihood of acquiring vaginal diseases or problems in postmenopausal women, wherein the vaginal diseases are selected from the group of diseases consisting of vaginal dryness, vulvo-vaginal dryness, vaginal pruritus, vaginal atrophy, atrophic vaginitis, dyspareunia, vaginal bleeding at sexual activity, sexual dysfunction, loss of libido, loss of compactness of collagen fibers of the vaginal wall, and low muscularis thickness of the vaginal w
